Clinical Trial Update: Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating a personalized neoantigen vaccine in combination with durvalumab (MEDI4736) for extensive-stage …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Personalized neoantigen vaccine

Snippet

Sponsor: Washington University School of Medicine | Conditions: Extensive-stage Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING